197721-29-2

Upstream product

• 79-37-8 oxalyl dichloride 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 95123-53-8 2-(but-3-en-1-yloxy)acetic acid 
• 1070998-06-9 But-3-enyloxy-acetyl chloride 

Downstream Products

• 197721-35-0 (S)-4-Benzyl-3-[(2S,3R)-2-but-3-enyloxy-6-(tert-butyl-diphenyl-silanyloxy)-3-hydroxy-hexanoyl]-oxazolidin-2-one 
• 197721-32-7 (4S)-3-<(2S,3R)-1-oxo-2-(but-3-enyl-1-oxy)-3-hydroxy-4-pentenyl>-4-benzyl-2-oxazolidinone 
• 239075-73-1 (4S)-3-<(2S,3R)-1-oxo-2-(but-3-enyl-1-oxy)-3-hydroxy-4-hexenyl>-4-benzyl-2-oxazolidinone 
• 197721-37-2 Acetic acid (R)-1-((R)-2-acetoxy-1-but-3-enyloxy-ethyl)-4-(tert-butyl-diphenyl-silanyloxy)-butyl ester 

Relevant academic research and scientific papers

SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS

The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

Oxazole derivatives

The present invention relates to novel oxazole compounds which act as PPARα and PPARγ agonists and are accordingly useful for the treatment of diseases modulated by PPARα and PPARγ such as diabetes.

An asymmetric aldol - Ring-closing metathesis strategy for the enantioselective construction of oxygen heterocycles: An efficient approach to the enantioselective synthesis of (+)-laurencin

A strategy is described for the enantioselective construction of medium- ring cyclic ethers by merging the asymmetric aldol addition of glycolates with a ring-closing metathesis reaction. Cyclic ethers of seven-, eight-, and nine-membered rings are readil